Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819474) titled 'Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Tumor Infiltrating Lymphocyte
CD8-PET
Advanced Melanoma
Intervention:
Drug: Crefmirlimb
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: February 18, 2027
Target Sample Size: 6
Countries of Recruitment:
United States
To know more...